Teva launches generic Delzicol

Press enter to search
Close search
Open Menu

Teva launches generic Delzicol

By Sandra Levy - 05/13/2019
Teva is introducing a generic version of Allergan’s Delzicol (mesalamine) delayed-release capsules in a 400 mg dosage strength.

Mesalamine delayed-release capsules are an aminosalicylate indicated for the treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older and for the maintenance of remission of ulcerative colitis in adults.

“Ulcerative colitis is a chronic inflammatory bowel disease and we’re proud to provide another treatment option for patients,” Teva's executive vice president and head of North America Commercial, Brendan O’Grady said.

Delzicol delayed-release capsules have a market value of roughly $130 million, according to February 2019 IQVIA data.

Related Topics